卡培他滨联合奥沙利铂治疗Ⅲ期结直肠癌疗效及对患者免疫功能、生活质量的影响

Clinical effect of capecitabine combined with oxaliplatin on patients with stage Ⅲ colorectal cancer and its impact to immune function and quality of life

目的 探讨卡培他滨联合奥沙利铂治疗Ⅲ期结直肠癌的临床疗效及对患者免疫功能、生活质量的影响.方法 选取62例Ⅲ期结直肠癌患者作为研究对象,随机纳入对照组（奥沙利铂联合5-氟尿嘧啶＋亚叶酸钙,FOLFOX4方案）和观察组（卡培他滨联合奥沙利铂,XELOX方案）中,每组31例.比较两组治疗效果及患者的免疫功能、生活质量情况.结果 两组治疗总有效率差异无统计学意义（P＞0.05）;观察组治疗后CD＋3、CD＋4及CD＋8细胞水平分别为（68.31±6.37）％、（43.58±4.24）％、（46.35±5.34）％,对照组治疗后CD＋3、CD＋4及CD＋8细胞水平依次为（57.72±5.26）％、（35.28±5.21）％、（38.76±4.42）％,两组治疗后以上指标较治疗前均明显上升,且观察组三项水平上升幅度显著大于对照组（t=15.09、6.88、7.14,均P＜0.05）.观察组治疗后情绪、角色、社会、躯体、认知各项评分及总分分别为（84.38±3.02）分、（82.36±3.03）分、（63.35±3.08）分、（89.24±4.05）分、（90.14±4.02）分、（69.53±4.28）分,对照组依次为（76.91±4.04）分、（73.82±3.07）分、（56.83±3.11）分、（86.42±4.04）分、（85.52±3.06）分、（54.49±4.32）分,两组治疗后各项及总评分均明显高于治疗前,观察组以上评分上升幅度显著大于对照组（t=8.25、11.02、8.29、2.75、5.09、13.77,均P＜0.05）.结论 卡培他滨联合奥沙利铂治疗Ⅲ期结直肠癌的治疗效果与常规FOLFOX4方案疗效相同,而且能明显改善免疫细胞功能并提高患者生活质量,值得临床推广应用.

Objective To explore clinical effect of capecitabine combined with oxaliplatin on stage Ⅲ colorectal cancer,as well as its impact to immune function and quality of life.Methods 62 cases with stage Ⅲ colorectal cancer were selected as research subjects,and they were randomly divided into control group （oxaliplatin combined with 5-fluorouracil ＋ calcium folinate,FOLFOX4 plan） and observation group （capecitabine combined with oxaliplatin,XELOX plan）,31 cases in each group.The clinical effect,immune function and quality of life were compared between the two groups.Results The total effective rate had no obvious difference between the two groups（P〉0.05）.The levels of CD＋3,CD＋4 and CD＋8 cells of the observation group were （68.31±6.37）%,（43.58±4.24）%,（46.35±5.34）%,respectively,which of the control group were （57.72±5.26）%,（35.28±5.21）%,（38.76±4.42）%,respectively.After treatment,the above indicators of the two groups were significantly higher than those before treatment,which of the observation group were significantly higher than those of the control group（t=15.09,6.88,7.14,all P〈0.05）.After treatment,the scores of emotion,role,social,physical,cognition and total scores of the observation group were （84.38±3.02）points,（82.36±3.03）points,（63.35±3.08）points,（89.24±4.05）points,（90.14±4.02）points,（69.53±4.28）points,respectively,which of the control group were （76.91±4.04）points,（73.82±3.07）points,（56.83±3.11）points,（86.42±4.04）points,（85.52±3.06）points,（54.49±4.32）points,respectively.After treatment,the scores of the two groups were significantly higher than those before treatment,which of the observation group were significantly higher than those of the control group （t=8.25,11.02,8.29,2.75,5.09,13.77,all P〈0.05）.Conclusion Capecitabine combined with oxaliplatin has similar clinical effect with routine FOLFOX4 plan on patients with stage Ⅲ colorectal cancer,and it can help patients to improve immune cell function and quality of life,so it is worthy to be promoted in clinical.